Clinicopathologic features of 67 patients with nasal NK cell lymphomas
Clinicopathologic features . | n . |
|---|---|
| Male/female | 52/15 |
| Median age (range) | 49 y (17-84 y) |
| Initial sites of tumor | |
| Nasal cavity | 30 |
| Nasal cavity + nasopharynx | 11 |
| Nasal cavity + naso/oropharynx | 11 |
| Nasal cavity + naso/oropharynx + cervical lymph nodes | 4 |
| Nasal cavity + naso/oropharyngx + distant metastases | 11 |
| Stage | |
| I | 51 |
| II | 5 |
| III | 5 |
| IV | 6 |
| Median LDH,* IU/mL (range) | 434 (144-2090) |
| ECOG performance score | |
| 0 | 5 |
| 1 | 47 |
| 2 | 13 |
| 3 | 2 |
| 4 | 0 |
| IPI score | |
| 0 | 11 |
| 1 | 24 |
| 2 | 24 |
| 3 | 7 |
| 4 | 1 |
Clinicopathologic features . | n . |
|---|---|
| Male/female | 52/15 |
| Median age (range) | 49 y (17-84 y) |
| Initial sites of tumor | |
| Nasal cavity | 30 |
| Nasal cavity + nasopharynx | 11 |
| Nasal cavity + naso/oropharynx | 11 |
| Nasal cavity + naso/oropharynx + cervical lymph nodes | 4 |
| Nasal cavity + naso/oropharyngx + distant metastases | 11 |
| Stage | |
| I | 51 |
| II | 5 |
| III | 5 |
| IV | 6 |
| Median LDH,* IU/mL (range) | 434 (144-2090) |
| ECOG performance score | |
| 0 | 5 |
| 1 | 47 |
| 2 | 13 |
| 3 | 2 |
| 4 | 0 |
| IPI score | |
| 0 | 11 |
| 1 | 24 |
| 2 | 24 |
| 3 | 7 |
| 4 | 1 |
The reference range of LDH has changed over time, owing to differences in the assay methodologies. The reference ranges were: before 1977, 50-200 U/L; 1977-1981, male: 131-275 U/L, female: 137-269 U/L; 1982-1985, 130-275 U/L; 1986 onward, male: 197-401 U/L, female: 200-360 U/L.